Get the Stockscreener App
3.83
0.79%
0.03
After Hours:
3.64
-0.19
-4.96%
Elutia Inc stock is traded at $3.83, with a volume of 84,757.
It is up +0.79% in the last 24 hours and up +1.06% over the past month.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
See More
Previous Close:
$3.80
Open:
$3.79
24h Volume:
84,757
Relative Volume:
2.01
Market Cap:
$130.45M
Revenue:
$35.35M
Net Income/Loss:
$-37.66M
P/E Ratio:
-1.7022
EPS:
-2.25
Net Cash Flow:
$-22.11M
1W Performance:
+16.06%
1M Performance:
+1.06%
6M Performance:
+30.72%
1Y Performance:
+179.56%
1-Day Range:
$3.715
$3.86
1-Week Range:
$3.1201
$3.88
52-Week Range:
$1.33
$5.24
Elutia Inc Stock (ELUT) Company Profile
Name
Elutia Inc
Sector
Industry
Phone
240-247-1143
Address
12510 PROSPERITY DRIVE, SILVER SPRING
Elutia Inc Stock (ELUT) Latest News
Short Interest in Elutia Inc. (NASDAQ:ELUT) Rises By 7.4% - MarketBeat
Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024 - The Manila Times
Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30 - The Manila Times
Individual investors among Elutia Inc.'s (NASDAQ:ELUT) largest stockholders and were hit after last week's 10% price drop - Simply Wall St
SILVERARC CAPITAL MANAGEMENT, LLC Acquires Shares in Elutia Inc - GuruFocus.com
Preclinical Data Show Efficacy Of Elutia's Antibiotic-Eluting BioEnvelope - MPO-mag
Elutia (NASDAQ:ELUT) vs. Curis (NASDAQ:CRIS) Head to Head Comparison - Defense World
Nantahala Capital Management LLC Grows Stock Position in Elutia Inc. (NASDAQ:ELUT) - Defense World
Nantahala Capital Management LLC Purchases 145,697 Shares of Elutia Inc. (NASDAQ:ELUT) - MarketBeat
Short Interest in Elutia Inc. (NASDAQ:ELUT) Declines By 30.1% - MarketBeat
Elutia Inc. (NASDAQ:ELUT) Sees Large Decrease in Short Interest - Defense World
Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company’s Antibiotic-Eluting BioEnvelope for Implantable Devices - StockTitan
Short Interest in Elutia Inc. (NASDAQ:ELUT) Decreases By 10.9% - MarketBeat
Elutia Announces First Patient Implant of EluPro™, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators - HMP Global Learning Network
Elutia announces first patient implant of EluPro, the world’s first drug-eluting bioenvelope for cardiac pacemakers and neurostimulators - Cardiovascular Business
AIGH Capital Management LLC Increases Position in Elutia Inc. (NASDAQ:ELUT) - MarketBeat
Cantor Fitzgerald Reiterates “Overweight” Rating for Elutia (NASDAQ:ELUT) - Defense World
Elutia Celebrates First Year - ForexTV.com
Elutia (NASDAQ:ELUT) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
Elutia Announces First Patient Implant of EluPro™, the - GlobeNewswire
Elutia to Participate in Upcoming Investor Conferences - ForexTV.com
Contaminated donor tissue gave Georgia patient tuberculosis, lawsuit says - The Atlanta Journal Constitution
Ryan Marques Joins Elutia As VP Of Operations - MPO-mag
Short Interest in Elutia Inc. (NASDAQ:ELUT) Expands By 468.3% - Defense World
Ryan Marques Joins Elutia as VP of Operations - MPO-mag
Elutia Inc. (NASDAQ:ELUT) Short Interest Update - MarketBeat
Spine Implant Caused Patient's TB, Suit Says - Law360
ELUT (Elutia) Financial Strength : 2 (As of Jun. 2024) - GuruFocus.com
ELUT (Elutia) Cash from Discontinued Operating Activities : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Elutia Inc. (ELUT) Q2 2024 Earnings Call Transcript - Seeking Alpha
Elutia (NASDAQ:ELUT) Price Target Cut to $10.00 - MarketBeat
Elutia Wins FDA Clearance Of Its Antibiotic-Eluting BioEnvelope - MPO-mag
Elutia Announces Second Quarter 2024 Results - StockTitan
Elutia (ELUT) Set to Announce Earnings on Wednesday - Defense World
Elutia Announces Full Exercise of Warrants Generating $15.7 Million in Gross Proceeds - StockTitan
Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year? - Yahoo Finance
Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations - citybiz
BioCardia Submits for FDA Approval of Morph DNA Steerable Introducer Product Family - Diagnostic and Interventional Cardiology
ELUTElutia Inc. Latest Stock News & Market Updates - StockTitan
Elutia Inc. (NASDAQ:ELUT) Sees Significant Drop in Short Interest - MarketBeat
Elutia Inc. (NASDAQ:ELUT) Sees Large Drop in Short Interest - Defense World
Beat the Market Like Zacks: Karooooo, UnitedHealth, Amgen in Focus - MSN
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire
Elutia Inc. (NASDAQ:ELUT) Short Interest Up 1,408.3% in June - Defense World
7 Growth Stocks to Buy for Under $5 for Massive Gains - InvestorPlace
Elutia Inc. (NASDAQ:ELUT) Sees Significant Growth in Short Interest - MarketBeat
Elutia to Present at the Emerging Growth Conference on Thursday, July 18 - StockTitan
Elutia Inc Stock (ELUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Elutia Inc Stock (ELUT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ferguson Matthew | CHIEF FINANCIAL OFFICER |
Mar 08 '24 |
Option Exercise |
0.00 |
1,288 |
0 |
121,807 |
0.47%
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):